Blood Cell Counters Market

Cell viability assessment, estimating cell concentrations for plating in culture, and evaluating the outcomes of cell isolation processes all need cell counting. It is advised to perform an initial cell count before performing cell isolation; the cell recovery can then be determined by comparing this number to the cell count following cell isolation. In addition, viable cell counts should be carried out in situations when a decline in cell viability may be anticipated, such as when working with cryopreserved cells or cells that have undergone ex vivo manipulation. One of the reasons influencing the blood cell counters market's expansion is the rising demand for biologics for the treatment of chronic diseases. The use of various cell counting tools during the development of biologics, including flow cytometers and spectrophotometers, helps manage the cell concentration in biologics and boosts the market's growth prospects. The COVID-19 had a significant effect on market expansion. As lymphopenia and eosinopenia were possible COVID-19 indications, the adoption of cell counting instruments significantly increased during the pandemic. 
Numerous research fields, including neuroscience, cancer biology, and immunology, which have lucrative market expansion prospects, are increasingly using cell counting tools. Blood cell counting is essential for the evaluation of numerous diseases, and its usage is likely to rise throughout the forecast period; therefore, the blood cell counters market is also expected to experience exponential growth. Moreover, they are widely employed in cancer research to control intra-tumor heterogeneity, which is crucial for figuring out how cancer progresses. For the purpose of disease monitoring and treatment targeting, cell counting is useful in identifying and classifying primary tumours, circulating tumours, and metastatic cancers.
Technology improvements in cell counting equipment and supplies-
Technological developments in blood cell counters  have enhanced product introductions and, as a result, adoption, which has in turn fueled this market expansion. For instance, the CountWire System was formally introduced in February 2021 by Logos Biosystems, a premier supplier of cutting-edge life science solutions and a branch of Aligned Genetics, Inc. Therefore, it is anticipated that factors such as the rising incidence of chronic diseases, expanding technological developments, and new releases in the cell counting market will propel the industry's expansion. However, the high cost of sophisticated cell counting equipment and haematology analyzer product recalls are projected to impede market growth.
Furthermore, during the study period, technical developments in these gadgets will present lucrative prospects. For instance, Merck introduced Scepter 3.0, an automated portable cell counting, in December 2020. Scepter 3.0 has a high degree of accuracy and can count hundreds of cells per measurement. The automated CytoSMART Exact FL, the company's first fluorescent cell counter, was released in April 2021 by CytoSMART Technologies. It is a dual-fluorescence instrument used in customary laboratory settings. Similar to this, DeNovix introduced the first imaging cell counter in June 2020, doing away with the need for slides and lessening the laboratory's impact on the environment.
Segment Overview:
By product type: Reagents, microplates, magnetic beads, and chamber slides are some of the consumables and accessories used with these gadgets. Their high usage volume is a contributing factor in the expansion of consumables and accessories. In addition, the introduction of innovative items spurs market expansion. In 2021, the subsegment for reagents had the highest revenue share. The significant revenue share is related to the frequent acquisition of these items for use in automated cell counting, flow cytometry, and spectrophotometry. These equipment' demand is heightened by the requirement for frequent calibrations before beginning experiments.
By application type: One of the most frequent tests performed to assess a person's general health is the complete blood count. Several blood components, including RBC, WBC, haemoglobin, hematocrit, and platelets, are measured by the test. Growing prevalence of blood illnesses including leukaemia and anaemia, which are frequently monitored by complete blood counts, is anticipated to fuel segment growth.
By end-use: Institutions engaged in academic and research, research generated the most money. The widespread use of cytometers in cell biology research investigations can be blamed for the large share. Researchers use cytometers to measure criteria like physical characteristics, kind, and lineage to track the evolution of viruses, diseases, and other bacteria.
By region: Throughout the projection period, North America is anticipated to maintain its sizeable market share in the blood cell counting industry. The significant market share is mostly attributable to the fact that there are more patients, more healthcare facilities are utilising automated haematology analyzers and high-throughput flow cytometry, and major market players are headquartered in the area. In addition, the increase in product releases by American businesses will encourage greater usage of these devices, fueling the expansion of this blood cell counters market in North America.
Competitive analysis and profiles of the major players in the blood cell counters, such as Agilent Technologies Inc., Becton, BioTek Instruments, Bio-Rad Laboratories, Danaher Corporation, Denovix Inc., Dickinson and Company, GE Healthcare, Merck & Co. Inc., PerkinElmer Inc., and Thermo Fisher Scientific, Inc. are provided in this report. Major players have adopted product launch and acquisition as key developmental strategies to improve the product portfolio of the blood cell counters market. 

 Blood Cell Counters Market Report Highlights